Low counts of Faecalibacterium prausnitzii in colitis microbiota
- PMID: 19235886
- DOI: 10.1002/ibd.20903
Low counts of Faecalibacterium prausnitzii in colitis microbiota
Abstract
Background: The intestinal microbiota is suspected to play a role in colitis and particularly in inflammatory bowel disease (IBD) pathogenesis. The aim was to compare the fecal microbiota composition of patients with colitis to that of healthy subjects (HS).
Methods: fecal samples from 22 active Crohn's disease (A-CD) patients, 10 CD patients in remission (R-CD), 13 active ulcerative colitis (A-UC) patients, 4 UC patients in remission (R-UC), 8 infectious colitis (IC) patients, and 27 HS were analyzed by quantitative real-time polymerase chain reaction (PCR) targeting the 16S rRNA gene. Bacterial counts were transformed to logarithms (Log(10) CFU) for statistical analysis.
Results: Bacteria of the phylum Firmicutes (Clostridium leptum and Clostridium coccoides groups) were less represented in A-IBD patients (9.7; P = 0.004) and IC (9.4; P = 0.02), compared to HS (10.8). Faecalibacterium prausnitzii species (a major representative of the C. leptum group) had lower counts in A-IBD and IC patients compared to HS (8.8 and 8.3 versus 10.4; P = 0.0004 and P = 0.003). The Firmicutes/Bacteroidetes ratio was lower in A-IBD (1.3; P = 0.0001) and IC patients (0.4; P = 0.002). Compared to HS, Bifidobacteria were less represented in A-IBD and IC (7.9 and 7.7 versus 9.2; P = 0.001 and P = 0.01).
Conclusions: The fecal microbiota of patients with IBD differs from that of HS. The phylum Firmicutes and particularly the species F. prausnitzii, are underrepresented in A-IBD patients as well as in IC patients. These bacteria could be crucial to gut homeostasis since lower counts of F. prausnitzii are consistently associated with a reduced protection of the gut mucosa.
Similar articles
-
Specificities of the fecal microbiota in inflammatory bowel disease.Inflamm Bowel Dis. 2006 Feb;12(2):106-11. doi: 10.1097/01.MIB.0000200323.38139.c6. Inflamm Bowel Dis. 2006. PMID: 16432374
-
Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis.Aliment Pharmacol Ther. 2013 Jul;38(2):151-61. doi: 10.1111/apt.12365. Epub 2013 Jun 3. Aliment Pharmacol Ther. 2013. PMID: 23725320
-
Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis.Am J Gastroenterol. 2012 Dec;107(12):1913-22. doi: 10.1038/ajg.2012.335. Epub 2012 Oct 9. Am J Gastroenterol. 2012. PMID: 23044767
-
Systematic review and meta-analysis of the role of Faecalibacterium prausnitzii alteration in inflammatory bowel disease.J Gastroenterol Hepatol. 2021 Feb;36(2):320-328. doi: 10.1111/jgh.15222. Epub 2020 Sep 7. J Gastroenterol Hepatol. 2021. PMID: 32815163
-
Gut microbiome diversity in acute infective and chronic inflammatory gastrointestinal diseases in North India.J Gastroenterol. 2016 Jul;51(7):660-71. doi: 10.1007/s00535-016-1193-1. Epub 2016 Mar 19. J Gastroenterol. 2016. PMID: 26994772 Review.
Cited by
-
Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease.J Gastroenterol. 2012 Dec;47(12):1298-307. doi: 10.1007/s00535-012-0605-0. Epub 2012 May 11. J Gastroenterol. 2012. PMID: 22576027
-
The human microbiome and its potential importance to pediatrics.Pediatrics. 2012 May;129(5):950-60. doi: 10.1542/peds.2011-2736. Epub 2012 Apr 2. Pediatrics. 2012. PMID: 22473366 Free PMC article. Review.
-
From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease.Therap Adv Gastroenterol. 2015 May;8(3):143-59. doi: 10.1177/1756283X15576462. Therap Adv Gastroenterol. 2015. PMID: 25949527 Free PMC article. Review.
-
Environmental risk factors for inflammatory bowel diseases: Evidence based literature review.World J Gastroenterol. 2016 Jul 21;22(27):6296-317. doi: 10.3748/wjg.v22.i27.6296. World J Gastroenterol. 2016. PMID: 27468219 Free PMC article. Review.
-
Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial.Nat Commun. 2024 Feb 23;15(1):1633. doi: 10.1038/s41467-024-45357-1. Nat Commun. 2024. PMID: 38395948 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical